Kraig Biocraft (KBLB) widens H1 2026 loss as auditors flag going concern risk
Kraig Biocraft Laboratories, Inc. reported no revenue for the three and six months ended June 30, 2026 and remains a development-stage company focused on recombinant spider silk fibers. The company posted a net loss of $909,535 for the quarter and $1,852,255 for the six months, compared with losses of $726,133 and $1,326,166 in the prior-year periods.
Cash and cash equivalents increased to $3,391,646 from $1,790,236 at December 31, 2025, primarily from raising $2,772,547 via a Standby Equity Purchase Agreement. Operating cash used was $1,128,413 for the six months. The balance sheet shows total assets of $4,271,792 and a stockholders’ deficit of $(6,751,116), improved from $(7,998,958) at year-end, but the company still has a working capital deficiency of $7,326,899.
Management explicitly states that these deficits and continued cash burn raise substantial doubt about the ability to continue as a going concern. The company carries a related-party note payable of $1,492,000 and related-party accounts payable and accrued expenses of $8,767,002, including accrued CEO salary and interest. Kraig also holds $440,652 in gold bullion and $3,281,516 in a government money market fund at fair value, and has expanded leasing and production commitments in Vietnam through multiple long-term operating leases.
Positive
- Cash position strengthened: Cash and cash equivalents rose to $3.39 million from $1.79 million, supported by $2.77 million raised through a Standby Equity Purchase Agreement, improving near-term liquidity despite ongoing losses.
- Stockholders’ deficit narrowed: Total stockholders’ deficit improved to $(6.75 million) from $(8.00 million) at December 31, 2025, reflecting fresh equity capital and non-cash contributions that partially offset accumulated losses.
Negative
- Going concern warning: Management discloses a working capital deficiency of $7.33 million, stockholders’ deficit of $(6.75 million), and operating cash use of $1.13 million, concluding there is substantial doubt about the company’s ability to continue as a going concern.
- Losses increasing with no revenue: The six-month net loss widened to $1.85 million from $1.33 million a year earlier, while revenue remained $0, indicating higher spending without offsetting commercial inflows.
- Large related-party obligations: Related-party accounts payable, accrued expenses and interest total $8.77 million, including a $1.49 million founder loan and significant accrued CEO compensation, creating balance-sheet and governance overhang.
Key Figures
Key Terms
going concern financial
Standby Equity Purchase Agreement financial
right-of-use asset financial
fair value option financial
anti-dilutive securities financial
original issue discount financial
Earnings Snapshot
FAQ
How much did Kraig Biocraft Laboratories (KBLB) lose in Q2 2026?
Did Kraig Biocraft Laboratories (KBLB) generate any revenue in the first half of 2026?
What is Kraig Biocraft Laboratories’ (KBLB) cash position and burn rate?
Why does Kraig Biocraft Laboratories (KBLB) have a going concern warning?
How is Kraig Biocraft Laboratories (KBLB) financing its operations?
What investments and hedging assets does Kraig Biocraft Laboratories (KBLB) hold?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
OR
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _____ to _____
Commission
File Number:
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation) |
(I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) |
(Registrant’s telephone number, including area code)
(Former name and address, if changed since last report)
Copies to:
Hunter Taubman Fischer & Li LLC
950 Third Ave., 19th Floor
New York, NY 10022
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||
| None | - | - |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and emerging growth company in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Smaller
reporting company | |
| Emerging
growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No
As
of August 13, 2026, there were
TABLE OF CONTENTS
| Page | |
| PART I FINANCIAL INFORMATION | |
| Item 1. Unaudited Condensed Financial Statements: | |
| Condensed Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025 (Audited) | 2 |
| Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended June 30, 2026, and 2025 | 3 |
| Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three and six months ended June 30, 2026 (Unaudited) | 4 |
| Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three and six months ended June 30, 2025 (Unaudited) | 5 |
| Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2026 | 6 |
| Notes to Condensed Consolidated Financial Statements (Unaudited) | 7 |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 30 |
| Item 3. Quantitative and Qualitative Disclosures about Market Risk | 38 |
| Item 4. Controls and Procedures | 38 |
| PART II OTHER INFORMATION | |
| Item 1. Legal proceedings | 39 |
| Item 1A. Risk Factors | 39 |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 39 |
| Item 3. Defaults upon Senior Securities | 39 |
| Item 4. Mine Safety Disclosures | 39 |
| Item 5. Other information | 39 |
| Item 6. Exhibits | 40 |
| 1 |
Kraig Biocraft Laboratories, Inc. and Subsidiary
Condensed Consolidated Balance Sheets
| June 30, 2026 | December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Inventory | ||||||||
| Prepaid expenses | ||||||||
| Total Current Assets | ||||||||
| Property and Equipment, net | ||||||||
| Investment in gold bullions (cost $ | ||||||||
| Operating lease right-of-use asset, net | ||||||||
| Security deposit | ||||||||
| Total Assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued expenses | $ | $ | ||||||
| Note payable - related party | ||||||||
| Royalty agreement payable - related party | ||||||||
| Accounts payable and accrued expenses - related party | ||||||||
| Accounts payable and accrued expenses | ||||||||
| Operating lease liability, current | ||||||||
| Total Current Liabilities | ||||||||
| Long Term Liabilities | ||||||||
| Operating lease liability, net of current | ||||||||
| Total Liabilities | ||||||||
| Commitments and Contingencies (Note 7) | - | - | ||||||
| Stockholders’ Deficit | ||||||||
| Preferred stock, | - | - | ||||||
| Preferred stock Series A, | ||||||||
| Preferred stock value | ||||||||
| Common stock Class A, | ||||||||
| Common stock Class B, | - | - | ||||||
| Common stock value | - | - | ||||||
| Common Stock Issuable, | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated Deficit | ( | ) | ( | ) | ||||
| Total Stockholders’ Deficit | ( | ) | ( | ) | ||||
| Total Liabilities and Stockholders’ Deficit | $ | $ | ||||||
| 2 |
Kraig Biocraft Laboratories, Inc. and Subsidiary
Consolidated Statements of Operations
(Unaudited)
| For the Three Months Ended | For the Six Months Ended | |||||||||||||||
| June 30, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | |||||||||||||
| Revenue | $ | - | $ | - | $ | - | $ | - | ||||||||
| Operating Expenses | ||||||||||||||||
| General and Administrative | ||||||||||||||||
| Professional Fees | ||||||||||||||||
| Officer’s Salary | ||||||||||||||||
| Research and Development | ||||||||||||||||
| Total Operating Expenses | ||||||||||||||||
| Loss from Operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other Income/(Expenses) | ||||||||||||||||
| Net change in unrealized depreciation on investment in gold bullion | ( | ) | ( | ) | ( | ) | ||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Gain on sale of gold | - | - | ||||||||||||||
| Interest income | ||||||||||||||||
| Total Other Income/(Expenses) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net (Loss) before Provision for Income Taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Provision for Income Taxes | - | - | - | - | ||||||||||||
| Net (Loss) | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net Income (Loss) Per Share - Basic and Diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average number of shares outstanding during the period - Basic and Diluted | ||||||||||||||||
| 3 |
Kraig Biocraft Laboratories, Inc. and Subsidiary
Condensed Consolidated Statement of Changes in Stockholders’ Deficit
For the three and six months ended June 30, 2026
(Unaudited)
| Shares | Par | Shares | Par | Shares | Par | Shares | Par | APIC | Deficit | Total | ||||||||||||||||||||||||||||||||||
| Preferred Stock - Series A | Common Stock - Class A | Common Stock - Class B | To be issued | Accumulated | ||||||||||||||||||||||||||||||||||||||||
| Shares | Par | Shares | Par | Shares | Par | Shares | Par | APIC | Deficit | Total | ||||||||||||||||||||||||||||||||||
| Balance, March 31, 2026 (Unaudited) | $ | $ | - | $ | - | $ | $ | $ | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Warrants issued for services - related parties | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Warrants issued for services | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Options issued for services | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Shares issued in connection with cashless warrants exercise | - | - | ( | ) | - | |||||||||||||||||||||||||||||||||||||||
| Imputed interest - related party | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Issuance of common stock | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Net loss for the three months ended June 30, 2026 | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
| Balance, June 30, 2026 (Unaudited) | $ | $ | - | $ | - | $ | $ | $ | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Balance, December 31, 2025 (Audited) | $ | $ | # | - | $ | - | $ | $ | $ | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
| Warrants issued for services - related parties | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Warrants issued for services | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Options issued for services | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Shares issued in connection with cashless warrants exercise | - | - | ( | ) | - | |||||||||||||||||||||||||||||||||||||||
| Imputed interest - related party | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Issuance of common stock | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Net loss for the six months ended June 30, 2026 | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
| Balance, June 30, 2026 (Unaudited) | $ | $ | - | $ | - | $ | $ | $ | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| 4 |
Kraig Biocraft Laboratories, Inc. and Subsidiary
Condensed Consolidated Statement of Changes in Stockholders’ Deficit
For the three and six months ended June 30, 2025
(Unaudited)
| Preferred Stock - Series A | Common Stock - Class A | Common Stock - Class B | To be issued | Accumulated | ||||||||||||||||||||||||||||||||||||||||
| Shares | Par | Shares | Par | Shares | Par | Shares | Par | APIC | Deficit | Total | ||||||||||||||||||||||||||||||||||
| Balance, March 31, 2025 (Audited) | $ | $ | - | $ | - | $ | $ | $ | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Warrants issued for services - related parties | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Warrants issued for services | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Options issued for services | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Imputed interest - related party | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Issuance of common stock, net of stock offering costs | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Net loss for the three months ended June 30, 2025 | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
| Balance, June 30, 2025 (Unaudited) | $ | $ | - | $ | - | $ | $ | $ | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Balance, December 31, 2024 (Audited) | $ | $ | # | - | $ | - | $ | $ | $ | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
| Balance | $ | $ | # | - | $ | - | $ | $ | $ | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
| Warrants issued for services - related parties | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Warrants issued for services | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Options issued for services | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Imputed interest - related party | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Issuance of common stock, net of stock offering costs | - | - | - | - | - | - | ( | ) | - | |||||||||||||||||||||||||||||||||||
| Issuance of common stock for commitment fee | - | - | - | - | - | - | ( | ) | - | - | ||||||||||||||||||||||||||||||||||
| Shares issued in connection with cashless warrants exercise | - | - | - | - | - | - | ( | ) | - | - | ||||||||||||||||||||||||||||||||||
| Net loss for the six months ended June 30, 2025 | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
| Balance, June 30, 2025 (Unaudited) | $ | $ | - | $ | - | $ | $ | $ | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Balance | $ | $ | - | $ | - | $ | $ | $ | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| 5 |
Kraig Biocraft Laboratories, Inc. and Subsidiary
Consolidated Statements of Cash Flows
(Unaudited)
| 2026 | 2025 | |||||||
| For the Six Months Ended June 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash Flows From Operating Activities: | ||||||||
| Net Loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operations | ||||||||
| Depreciation expense | ||||||||
| Net change in unrealized depreciation (appreciation) and depreciation in gold bullions | ( | ) | ||||||
| Gain on sale of gold bullions | - | ( | ) | |||||
| Imputed interest - related party | ||||||||
| Fair value of options issued for services | ||||||||
| Warrants issued/(cancelled) to consultants | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| (Increase) Decrease prepaid expenses | ( | ) | ||||||
| (Increase) in inventory | ( | ) | - | |||||
| Decrease in operating lease right-of-use, net | ||||||||
| Increase in accrued expenses and other payables - related party | ||||||||
| (Decrease) Increase in accounts payable | ( | ) | ||||||
| Decrease in operating lease liabilities, current | ( | ) | ( | ) | ||||
| Net Cash Used In Operating Activities | ( | ) | ( | ) | ||||
| Cah Flows from Investing Activities | ||||||||
| Proceeds from sale of investment in gold | - | |||||||
| Purchase of fixed assets | ( | ) | ( | ) | ||||
| Net Cash Provided (Used in) by Investing Activities | ( | ) | ||||||
| Cash Flows From Financing Activities: | ||||||||
| Proceeds from Standby Equity Purchase Agreement | ||||||||
| Payment of debt offering costs | - | ( | ) | |||||
| Net Cash Provided by Financing Activities | ||||||||
| Net Change in Cash and Cash Equivalents | ||||||||
| Cash and Cash Equivalents at Beginning of Period | ||||||||
| Cash and Cash Equivalents at End of Period | $ | $ | ||||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest | $ | - | $ | - | ||||
| Cash paid for taxes | $ | - | $ | - | ||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Adoption of lease standard ASC 842 | $ | $ | - | |||||
| Common shares issued in connection with Standby Equity Purchase Agreement - Commitment Share fee | $ | - | $ | |||||
| Shares issuable in connection with cashless warrant exercise | $ | $ | ||||||
| 6 |
Kraig Biocraft Laboratories, Inc.
Notes to Condensed Consolidated Financial Statements as of June 30, 2026
(Unaudited)
NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION
Basis of Presentation
The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.
In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all of the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2026 and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2026 are not necessarily indicative of the operating results for the full fiscal year or any future period.
These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 30, 2026.
Management acknowledges its responsibility for the preparation of the accompanying unaudited consolidated financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its consolidated financial position and the consolidated results of its operations for the periods presented.
Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries.
On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary.
On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd.
On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd.
On January 24, 2024, the Company signed a memorandum of understanding with the Vietnam Sericulture Association (“VSA”) and the Lam Dong Agro-Forestry Research & Experiment Center (“LAREC”) to enhance sericulture in Vietnam through the expanded application of the Company’s spider silk silkworm technology.
| 7 |
On January 14, 2025, the Company was granted a new Investment Registration Certificate and an Enterprise Registration Certificate for its production operations in Vietnam. This registration formed a new subsidiary, Prodigy Silk Co., Ltd.
On January 12, 2026, the Company dissolved Prodigy Textiles Co., Ltd, and transferred all of its production operations into Prodigy Silk Co., Ltd. Vietnamese Law required a new business name for the Company’s new Enterprise Registration Certificate issued in 2025.
Foreign Currency
The assets and liabilities of Prodigy Textiles, Co., Ltd. and Prodigy Silk Co., Ltd. (the Company’s Vietnamese subsidiaries) whose functional currencies are the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date.
Use of Estimates
In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.
Cash and Cash Equivalents
Cash and cash equivalents consist of demand deposits at financial institutions, money market funds, and highly liquid investments with original maturities of three months or less.
As
of June 30, 2026, and December 31, 2025, the Company had $
Loss Per Share
Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For June 30, 2026, and December 31, 2025, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive.
The computation of basic and diluted loss per share for June 30, 2026, and December 31, 2025 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive:
SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNING PER SHARE
| June 30, 2026 | December 31, 2025 | |||||||
| Stock Warrants (Exercise price - $ | ||||||||
| Stock Options (Exercise price - $ | ||||||||
| Convertible Preferred Stock | ||||||||
| Common Stock Payable | ||||||||
| Total | ||||||||
| 8 |
Research and Development Costs
The Company expenses all research and development costs as incurred, for which there is no alternative future use.
For
the three months ended June 30, 2026, and 2025, the Company had $
For
the six months ended June 30, 2026, and 2025, the Company had $
Advertising Expense
The
Company follows the policy of charging the costs of advertising to expense as incurred. There was
Income Taxes
The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
Stock-Based Compensation
The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life (The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations.
The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASU 2018-07.
RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS
ASU 2025-05 — Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets
In July 2025, the FASB issued ASU 2025-05, which provides (1) all entities with a practical expedient and (2) entities other than public business entities with an accounting policy election when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under Topic 606, Revenue from Contracts with Customers.
The practical expedient allows an entity to assume that, when estimating expected credit losses, current conditions as of the balance sheet date remain unchanged for the remaining life of the asset. The accounting policy election permits non-public entities that elect the practical expedient to also consider collection activity occurring after the balance sheet date when estimating expected credit losses.
| 9 |
The standard is effective for fiscal years beginning after December 15, 2025, and for interim periods within those annual reporting periods. Early adoption is permitted.
The Company has evaluated ASU 2025-05 and does not expect the standard to have a material impact on its financial condition, results of operations, or cash flows.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures, to require enhanced disclosures that include reportable segment expenses. The amendments in this update provide that a business entity disclose significant segment expenses, segment profit or loss (after significant segment expenses), and allows reporting of additional measures of a segments profit or loss if used in assessing segment performance. Such disclosures apply to entities with a single reportable segment. These amendments were effective for the Company in 2024 and retrospectively to all prior periods using the significant segment expense categories identified. The impact of the adoption of the amendments in this update was not material to the Company’s consolidated financial position and results of operations, as the requirements impact only segment reporting disclosures in the footnotes to the Company’s consolidated financial statements.
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses including purchases of inventory, employee compensation, depreciation and intangible asset amortization in commonly presented expense captions such as cost of sales, selling, general and administrative expense, and research and development. These amendments are effective for the Company for annual periods in 2027, applied prospectively, with early adoption permitted, and interim periods beginning in 2028. The Company intends to adopt the amendments in this update prospectively in 2027 for annual periods and in 2028 for interim periods. The impact of the adoption of the amendments in this update is not expected to be material to the Company’s consolidated financial position and results of operations, as the requirements only require more detailed disclosures in the footnotes to the Company’s consolidated financial statements.
In March 2024, the FASB issued ASU No. 2024-02, Codification Improvements - Amendments to Remove References to the Concepts Statements to remove various references to concepts statements from the FASB Accounting Standards Codification. This guidance is to clarify guidance, simplify wording or structure of guidance, and other minor improvements. These amendments are effective for the Company for annual periods in 2025, applied prospectively, with early adoption and retrospective application permitted. The Company intends to adopt the amendments in this update prospectively in 2025. The impact of the adoption of the amendments in this update is not expected to be material to the Company’s consolidated financial position and results of operations.
In March 2024, the FASB issued ASU No. 2024-01, Compensation - Stock Compensation (Topic 718) - Scope Application of Profits Interest and Similar Awards, to clarify whether profits interest and similar awards should be accounted for in accordance with Topic 718, Compensation - Stock Compensation. The guidance applies to all business entities that issue profits interest awards as compensation to employees or nonemployees in exchange for goods or services. These amendments are effective for the Company for annual and interim periods in 2025, applied prospectively, with early adoption and retrospective application permitted. As the Company does not issue profit interest awards, the impact of the adoption of the amendments in this update is not expected to be material to the Company’s consolidated financial position and results of operations.
| 10 |
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures, to require enhanced income tax disclosures to provide information to assess how an entity’s operations and related tax risks, tax planning, and operational opportunities affect its tax rate and prospects for future cash flows. The amendments in this update provide that a business entity disclose (1) a tabular income tax rate reconciliation, using both percentages and amounts, (2) separate disclosure of any individual reconciling items that are equal to or greater than 5% of the amount computed by multiplying the income (loss) from continuing operations before income taxes by the applicable statutory income tax rate, and disaggregation of certain items that are significant and (3) amount of income taxes paid (net of refunds received) disaggregated by federal, state and foreign jurisdictions, including separate disclosure of any individual jurisdictions greater than 5% of total income taxes paid. These amendments are effective for the Company for annual periods in 2025, applied prospectively, with early adoption and retrospective application permitted. The Company intends to adopt the amendments in this update prospectively in 2025. The impact of the adoption of the amendments in this update is not expected to be material to the Company’s consolidated financial position and results of operations, since the amendments require only enhancement of existing income tax disclosures in the footnotes to the Company’s consolidated financial statements.
Equipment
The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life.
In accordance with FASB ASC No. 360, Property, Plant and Equipment, the Company carries long-lived assets at the lower of the carrying amount or fair value. Impairment is evaluated by estimating future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected undiscounted future cash flow is less than the carrying amount of the assets, an impairment loss is recognized. Fair value, for purposes of calculating impairment, is measured based on estimated future cash flows, discounted at a market rate of interest.
Fair Value of Financial Instruments
We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” (“ASC Topic 820-10”). ASC Topic 820-10 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). ASC Topic 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Level 1 instruments include cash and cash equivalents, account receivable, prepaid expenses, inventory and account payable and accrued liabilities. The carrying values are assumed to approximate the fair value due to the short term nature of the instrument.
The three levels of the fair value hierarchy under ASC Topic 820-10 are described below:
| ● | Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at December 31, 2025, and 2024. | |
| ● | Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. | |
| ● | Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. |
| 11 |
The following are the major categories of assets measured at fair value on a recurring basis: as of June 30, 2026, and December 31, 2025, using quoted prices in active markets for identical liabilities (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):
The Company has consistently applied the valuation techniques in all periods presented. The following table presents the Company’s assets which were measured at fair value at June 30, 2026, and December 31, 2025:
SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS
| June 30, 2026 | December 31, 2025 | |||||||||||||||||||||||||||||||
| Fair Value Measurement Using | Fair Value Measurement Using | |||||||||||||||||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||||
| Assets: | ||||||||||||||||||||||||||||||||
| Investment in gold | $ | $ | - | $ | - | $ | $ | $ | - | $ | - | $ | ||||||||||||||||||||
| Money market fund | $ | $ | - | $ | - | $ | $ | $ | - | $ | - | $ | ||||||||||||||||||||
| Total | $ | $ | - | $ | - | $ | $ | $ | - | $ | - | $ | ||||||||||||||||||||
The Board of Directors, who serves as the Custodian, is responsible for the safekeeping of gold bullion owned by the Company.
Valuation of Gold Bullion
The investment in Bullion is classified as a level 1 asset, as the Company’s investment in Bullion is calculated using unadjusted quoted prices from primary market sources.
Gains and Losses on Gold Bullion
Fair value of the gold bullion held by the Company is based on that day’s London Bullion Market Association (“LBMA”) Gold Price PM. “LBMA Gold Price PM” is the price per fine troy ounce of gold, stated in U.S. dollars, determined by ICE Benchmark Administration (“IBA”) following an electronic auction consisting of one or more 30-second rounds starting at 3:00 p.m. (London time), on each day that the London gold market is open for business and published shortly thereafter.
The Company holds gold bullion as part of its strategy to manage inflation risk and diversify its assets. Upon acquisition, the Company elected the Fair Value Option under ASC 825-10, Financial Instruments – Fair Value Option to account for its investment in gold bullion. This election is irrevocable and was made to better reflect the Company’s intent to manage the assets based on fair value fluctuations.
Accounting Policy and Election
The Company follows the provisions of ASC 820, Fair Value Measurement (“ASC 820”). ASC 820 provides guidance for determining fair value and requires increased disclosure regarding the inputs to valuation techniques used to measure fair value. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
The Company recognizes changes in fair value of the investment in Bullion as changes in unrealized gains or losses on investment in Bullion through the Statement of Operations.
In accordance with ASC 825-10, the Company has elected to measure its gold bullion at fair value with changes in fair value recognized in earnings. The gold bullion qualifies for the fair value option as it is a non-financial asset that is managed and evaluated on a fair value basis.
| ● | The fair value option was elected at initial recognition of the gold bullion. | |
| ● | Changes in fair value are recognized in “Other (Income) Expense, Net” in the Consolidated Statements of Operations. |
For
the three months ended June 30, 2026 and 2025, the Company recognized an unrealized loss of $
For
the six months ended June 30, 2026 and 2025, the Company recognized an unrealized loss of $
| 12 |
Storage and Custody
The Company holds its gold bullion in a segregated vault operated by an independent third-party custodian. The Company periodically verifies the existence and condition of the gold through physical inspections and independent third-party audits.
The following tables summarize activity in gold bullion for the three months ended June 30, 2026:
SCHEDULE OF GOLD IN BULLION
| Six Months Ended June 30, 2026 | Ounces | Cost | Fair Value | |||||||||
| Balance December 31, 2025 | $ | $ | ||||||||||
| Net change in unrealized loss | - | ( | ) | |||||||||
| Balance June 30, 2026 | $ | $ | ||||||||||
Money Market Funds
Money market funds included in cash and cash equivalents and U.S. government-backed securities are measured at fair value based on quoted prices in active markets, which are considered Level 1 inputs. The Company’s policy is to recognize transfers in and/or out of the fair value hierarchy as of the date in which the event or change in circumstances caused the transfer.
Revenue Recognition
Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.
For the three and six months ended June 30, 2026, and 2025, the Company recognized $0 and $0 respectively in revenue.
Concentration of Credit Risk
The
Company at times has cash and cash equivalents in banks in excess of FDIC insurance limits. At June 30, 2026, and December 31, 2025,
the Company had approximately $
On
March 12, 2023, the U.S. government took extraordinary steps to stop a potential banking crisis after the historic failure of Silicon
Valley Bank, assuring all depositors at the failed institution that they could access all their money quickly, even as another major
bank was shut down. The Company had no exposure to a failed bank. The Company averts risks associated with such a crisis by holding minimum
cash balances required for uninterrupted operations, federal funds money market fund, and U.S. government-backed securities. As of June
30, 2026 and December 31, 2025, the Company held $
| 13 |
Original Issue Discount
For certain notes issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded as a debt discount, reducing the face amount of the note, and is amortized to amortization of original issue discount in the consolidated statements of operations over the life of the debt.
Debt Issue Cost
Debt issuance cost paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense in the consolidated statements of operations, over the life of the underlying debt instrument.
Investments without a Readily Determinable Fair Value (Cost Method)
Investments in nonmarketable entities in which the Company is not able to exercise significant influence, our “Cost Method Investments,” are accounted for at our initial cost, minus any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
The
Company holds a
Inventory
Inventory is stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out “FIFO” method and includes the purchase price and other costs incurred to bring the inventory to its present location and condition.
The Company’s inventory primarily consists of in-process materials such as wet and dry cocoons as well as reeled silk held for additional production processing and commercial sales. The Company periodically evaluates inventory for deterioration, damage, excess quantities, obsolescence and changes in expected future use or estimated net realizable value. When the carrying value of inventory exceeds its estimated net realizable value, the Company records a write-down to reduce the inventory to its estimated net realizable value.
Materials consumed in research and development activities are charged to research and development expenses when used. Materials acquired for a specific research and development project that have no alternative future use are expensed as incurred.
During
the six months ended June 30, 2026, the Company recorded an inventory write-down of $
At
June 30, 2026 inventory was $
Segment Reporting
Operating
segments are defined as components of an enterprise that have the following characteristics: (i) they engage in business activities from
which they may earn revenue and incur expense, (ii) their operating results are regularly reviewed by the chief operating decision maker
(“CODM”) for resource allocation decisions and performance assessment, and (iii) their discrete financial information is
available. Our CODM is our Chief Executive Officer, who manages and allocates resources to our operations on a consolidated basis. We
operate as
NOTE 2 GOING CONCERN
As
reflected in the accompanying financial statements, the Company has a working capital deficiency of $
Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.
| 14 |
NOTE 3 EQUIPMENT
At June 30, 2026, and December 31, 2025, property and equipment, net, is as follows:
SCHEDULE OF PROPERTY AND EQUIPMENT
| June 30, 2026 | December 31, 2025 | Estimated Useful Lives (Years) | ||||||||||
| Automobile | $ | $ | ||||||||||
| Laboratory Equipment | ||||||||||||
| Office Equipment | ||||||||||||
| Leasehold Improvements | ||||||||||||
| Property and Equipment, gross | 2-5 | |||||||||||
| Less: Accumulated Depreciation | ( | ) | ( | ) | ||||||||
| Total Property and Equipment, net | $ | $ | ||||||||||
Depreciation
expense for the three months ended June 30, 2026, and 2025, was $
Depreciation
expense for the six months ended June 30, 2026, and 2025, was $
NOTE 4 - RIGHT TO USE ASSETS AND LEASE LIABILITY
We determine if an arrangement is a lease, or contains a lease, at inception and record the leases in our financial statements upon lease commencement, which is the date when the underlying asset is made available for use by the lessor.
We have a lease agreement with lease and non-lease components and have elected to utilize the practical expedient to account for lease and non-lease components together as a single combined lease component, from both a lessee and lessor perspective with the exception of direct sales-type leases and production equipment classes embedded in supply agreements. From a lessor perspective, the timing and pattern of transfer are the same for the non-lease components and associated lease component and, the lease component, if accounted for separately, would be classified as an operating lease.
We have elected not to present short-term leases on the balance sheet as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that we are reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because our lease does not provide an implicit rate of return, we used our incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments.
In general, leases, where we are the lessee, may include options to extend the lease term. These leases may include options to terminate the lease prior to the end of the agreed upon lease term. For purposes of calculating lease liabilities, lease terms include options to extend or terminate the lease when it is reasonably certain that we will exercise such options.
Lease expense for operating leases is recognized on a straight-line basis over the lease term as cost of revenues or operating expenses depending on the nature of the leased asset. Certain operating leases provide for annual increases to lease payments based on an index or rate. We calculate the present value of future lease payments based on the index or rate at the lease commencement date.
Differences between the calculated lease payment and actual payment are expensed as incurred. Amortization of finance lease assets is recognized over the lease term as cost of revenues or operating expenses depending on the nature of the leased asset.
Interest expense on finance lease liabilities is recognized over the lease term in interest expense.
Since
September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place
of business. We pay an annual rent of $
| 15 |
On
September 5, 2019, we signed a
We pay annual rent as follows:
SCHEDULE OF ANNUAL RENT PAYMENT
| Lease Term | Annual Rent | |||||||
| $ | ||||||||
| $ | ||||||||
| $ | ||||||||
On
July 1, 2021, the Company signed a
On
January 31, 2024, the Company signed a
On
September 20, 2024, the Company signed a
| Lease Term | Annual Rent | |||||||
| $ | ||||||||
| $ | ||||||||
| $ | ||||||||
On
January 1, 2026, the Company signed a
| Lease Term | Annual Rent | |||||||
| $ | ||||||||
| $ | ||||||||
The
Company recorded ROU asset of $
On
March 31, 2026, the Company signed a
| Lease Term | Annual Rent | |||||||
| $ | ||||||||
| $ | ||||||||
| $ | ||||||||
The
Company recorded ROU asset of $
On
April 23, 2026, the Company signed a
| Lease Term | Annual Rent | |||||||
| $ | ||||||||
| $ | ||||||||
| $ | ||||||||
| $ | ||||||||
| $ | ||||||||
The
Company recorded ROU asset of $
On
April 28, 2026, the Company signed a
| Lease Term | Annual Rent | |||||||
| $ | ||||||||
| $ | ||||||||
The
Company recorded ROU asset of $
On
May 13, 2026, the Company signed a
| Lease Term | Annual Rent | |||||||
| $ | ||||||||
| $ | ||||||||
| $ | ||||||||
The
Company recorded ROU asset of $
| 16 |
The tables below present information regarding the Company’s operating lease assets and liabilities at June 30, 2026:
At June 30, 2026, and December 31, 2025, the Company had no financing leases as defined in ASC 842, “Leases.”
SCHEDULE OF OPERATING LEASE ASSETS AND LIABILITIES
| June 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Operating lease - right-of-use asset - non-current | $ | $ | ||||||
| Liabilities | ||||||||
| Operating lease liability | $ | $ | ||||||
| Weighted-average remaining lease term (years) | ||||||||
| Weighted-average discount rate | % | % | ||||||
| The components of lease expense were as follows: | ||||||||
| Operating lease costs | ||||||||
| Amortization of right-of-use operating lease asset | $ | $ | ||||||
| Impairment of right of use asset | $ | - | - | |||||
| Total operating lease costs | $ | $ | ||||||
| Supplemental cash flow information related to operating leases was as follows: | ||||||||
| Operating cash outflows from operating lease (obligation payment) | $ | $ | ||||||
| Right-of-use asset obtained in exchange for new operating lease liability | $ | $ | ||||||
| Impairment of right of use asset | $ | - | $ | - | ||||
| Net | $ | - | $ | - | ||||
Future minimum lease payments required under leases that have initial or remaining non-cancellable lease terms in excess of one year at June 30, 2026:
SCHEDULE OF MINIMUM LEASE PAYMENTS
| 2026 (6 months) | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| 2030 and beyond | ||||
| Total lease payments | ||||
| Less: amount representing interest | ( | ) | ||
| Total lease obligations | ||||
| Less: current portion of operating lease liability | ( | ) | ||
| Long-term portion operating lease liability | $ |
NOTE 5 NOTE PAYABLE – RELATED PARTY
Between
June 6, 2016, and December 1, 2020 the Company received a total of $
On
January 26, 2022, the Company repaid $
On
August 26, 2025, the Company repaid $
On
December 16, 2025, the Company repaid $
| 17 |
Total
loan payable to the founder and CEO for as of June 30, 2026, is $
Total
loan payable to the founder and CEO as of December 31, 2025, is $
During
the six months ended June 30, 2026, the Company recorded $
During
the six months ended June 30, 2025, the Company recorded $
During
the years ended December 31, 2025, the Company recorded $
As
of June 30, 2026, total interest payable is $
As
of December 31, 2025, total interest payable is $
NOTE 6 STOCKHOLDERS’ DEFICIT
(A) Common Stock Issued for Cash
On
January 21, 2025, the Company entered into a Standby Equity Purchase Agreement with an investor granting the Company the rights to sell
up to $
During
the six months ended June 30, 2026, the Company sold
During
the years ended December 31, 2025, the Company sold
(B) Common Stock Issued for Services
Shares issued for services as mentioned below were valued at the closing price of the stock on the date of grant.
None issued for the six months ended June 30, 2026.
On
July 9, 2025, the Company issued
On
July 16, 2025, the Company issued
(C) Common Stock Warrants and Options
On
May 4, 2026, the Company issued
On
March 14, 2025, the Company issued
On
July 1, 2025, the Company issued
During
the years ending December 31, 2025 the Company had
| 18 |
On
January 15, 2026 the Company issued a
SCHEDULE OF OPTION ASSUMPTION
| Expected dividends | % | |||
| Expected volatility | % | |||
| Expected term | ||||
| Risk free interest rate | % | |||
| Expected forfeitures | % |
On
October 22, 2025, the Company issued a
| ● | ||
| ● |
| Expected dividends | % | |||
| Expected volatility | % | |||
| Expected term | ||||
| Risk free interest rate | % | |||
| Expected forfeitures | % |
On
July 10, 2025, the Company issued a
| Expected dividends | % | |||
| Expected volatility | % | |||
| Expected term | ||||
| Risk free interest rate | % | |||
| Expected forfeitures | % |
On
July 10, 2025, the Company issued a
| Expected dividends | % | |||
| Expected volatility | % | |||
| Expected term | ||||
| Risk free interest rate | % | |||
| Expected forfeitures | % |
| 19 |
On
April 1, 2025, the Company issued a
| ● | ||
| ● | ||
| ● |
During
the three months ended June 30, 2026, the Company recorded $
| Expected dividends | % | |||
| Expected volatility | % | |||
| Expected term | ||||
| Risk free interest rate | % | |||
| Expected forfeitures | % |
On
October 1, 2024, the Company issued a
| Expected dividends | % | |||
| Expected volatility | % | |||
| Expected term | ||||
| Risk free interest rate | % | |||
| Expected forfeitures | % |
On
August 6, 2024, the Company issued a
| Expected dividends | % | |||
| Expected volatility | % | |||
| Expected term | ||||
| Risk free interest rate | % | |||
| Expected forfeitures | % |
| 20 |
On
August 6, 2024, the Company issued a
| Expected dividends | % | |||
| Expected volatility | % | |||
| Expected term | ||||
| Risk free interest rate | % | |||
| Expected forfeitures | % |
On
August 6, 2024, the Company issued a
| Expected dividends | % | |||
| Expected volatility | % | |||
| Expected term | ||||
| Risk free interest rate | % | |||
| Expected forfeitures | % |
On
August 6, 2024 the Company issued a
| Expected dividends | % | |||
| Expected volatility | % | |||
| Expected term | ||||
| Risk free interest rate | % | |||
| Expected forfeitures | % |
On
December 13, 2023, the Company issued a
| Expected dividends | % | |||
| Expected volatility | % | |||
| Expected term | ||||
| Risk free interest rate | % | |||
| Expected forfeitures | % |
| 21 |
On
December 13, 2023, the Company issued a
| Expected dividends | % | |||
| Expected volatility | % | |||
| Expected term | ||||
| Risk free interest rate | % | |||
| Expected forfeitures | % |
Warrant activity as of June 30, 2026 is summarized as follows:
SCHEDULE OF WARRANTS ACTIVITY
| Warrants | Number of Warrants | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value | ||||||||||||
| Outstanding – December 31, 2025 | $ | $ | ||||||||||||||
| Exercisable – December 31, 2025 | $ | $ | ||||||||||||||
| Granted | - | $ | - | - | – | |||||||||||
| Exercised | ( | ) | $ | ( | ) | – | – | |||||||||
| Cancelled/Forfeited | ( | ) | $ | – | – | |||||||||||
| Outstanding – June 30, 2026 | $ | $ | ||||||||||||||
| Exercisable – June 30, 2026 | $ | $ | ||||||||||||||
As of June 30, 2026, the following warrants were outstanding:
SCHEDULE OF WARRANTS OUTSTANDING
Exercise Price Warrants Outstanding | Warrants Exercisable | Weighted Average Remaining Contractual Life | Aggregate Intrinsic Value | |||||||||||
| $ | $ | |||||||||||||
| $ | $ | – | ||||||||||||
| $ | $ | – | ||||||||||||
| $ | $ | – | ||||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | - | ||||||||||||
| $ | $ | - | ||||||||||||
| $ | $ | - | ||||||||||||
| $ | $ | - | ||||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | $ | ||||||||||||
| 22 |
As of December 31, 2025, the following warrants were outstanding:
Exercise Price Warrants Outstanding | Warrants Exercisable | Weighted Average Remaining Contractual Life | Aggregate Intrinsic Value | |||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | – | ||||||||||||
| $ | $ | – | ||||||||||||
| $ | $ | – | ||||||||||||
| $ | $ | – | ||||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | |||||||||||||
| $ | $ | – | ||||||||||||
| $ | $ | – | ||||||||||||
| $ | $ | – | ||||||||||||
| $ | $ | – | ||||||||||||
| $ | $ | - | ||||||||||||
| $ | $ | - | ||||||||||||
| $ | $ | |||||||||||||
Options activity as of June 30, 2025 is summarized as follows:
SCHEDULE OF OPTIONS ACTIVITY
| Options | Number of Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value | ||||||||||||
| Outstanding – December 31, 2025 | $ | $ | – | |||||||||||||
| Exercisable – December 31, 2025 | $ | $ | – | |||||||||||||
| Granted | $ | – | ||||||||||||||
| Exercised | – | $ | – | – | – | |||||||||||
| Cancelled/Forfeited | – | $ | – | – | – | |||||||||||
| Outstanding – June 30, 2026 | $ | $ | – | |||||||||||||
| Exercisable – June 30, 2026 | $ | $ | – | |||||||||||||
| 23 |
For the three months ended June 30, 2026, the following options were outstanding:
SCHEDULE OF OPTIONS OUTSTANDING
Exercise Price | Options Outstanding | Options Exercisable | Weighted Average Remaining Contractual Life (in Years) | |||||||||||
| $ | ||||||||||||||
For the years ended December 31, 2025, the following options were outstanding:
Exercise Price | Options Outstanding | Options Exercisable | Weighted Average Remaining Contractual Life (in Years) | |||||||||||
| $ | ||||||||||||||
(C) Amendment to Articles of Incorporation
On February 16, 2009, the Company amended its articles of incorporation to amend the number and class of shares the Company is authorized to issue as follows:
| ● | Common
stock Class A, unlimited number of shares authorized, |
| ● | Common
stock Class B, unlimited number of shares authorized, |
| ● | Preferred
stock, unlimited number of shares authorized, |
Effective
December 17, 2013, the Company amended its articles of incorporation to designate a Series A no par value preferred stock.
On
March 26, 2024, the Company increased the total authorized Series A preferred stock to
On
March 26, 2024, the Company issued
NOTE 7 COMMITMENTS AND CONTINGENCIES
Agreements
On
November 10, 2010, the Company entered into an employment agreement with its CEO, effective January 1, 2011 through the December 31,
2015. The term of the agreement is a
| 24 |
On
January 20, 2015, the board of directors appointed Mr. Jonathan R. Rice as our Chief Operating Officer. Mr. Rice’s employment
agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment
agreement, Mr. Rice is entitled to an annual cash compensation of $
As
of June 30, 2026, and December 31, 2025, the Company owes $
On
July 3, 2019, the board of directors appointed Mr. Kenneth Le as the Company’s Director of Government relations and President
of Prodigy Textiles. On January 14, 2025 the board of directors appointed Mr. Le as the president of Prodigy Silk. Mr. Le’s
employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the
employment agreement, Mr. Le is entitled to annual cash compensation of $
On
May 4, 2026, the Company signed an agreement with public relations firm Oak Street Communications. Under the terms of that agreement
the Company will pay compensation of $
Legal Matters
The Company may be involved in legal actions and claims arising in the ordinary course of business, from time to time, none of which at the time are considered to be material to the Company’s business or financial condition.
(A) License Agreement
On
December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with Mr. Thompson, its CEO. In
accordance with FASB ASC No 480, Distinguishing Liabilities from Equity, the Company determined that the present value of the
payment of $
| 25 |
(B) Operating Lease Agreements
Since
September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place
of business. We pay an annual rent of $
On
September 20, 2024, the Company signed a
SCHEDULE OF ANNUAL RENT
| Lease Term | Annual Rent | |||||||
| $ | ||||||||
| $ | ||||||||
| $ | ||||||||
On
January 31, 2024, the Company signed a
On
July 1, 2021, the Company signed a
On
September 13, 2017, the Company signed a
| Lease Term | Annual Rent | |||||||
| $ | ||||||||
| $ | ||||||||
| $ | ||||||||
| 26 |
NOTE 8 RELATED PARTY TRANSACTIONS
Accounts payable and accrued expenses – related party consists of the following:
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES RELATED PARTY
| As of June 30, 2026 | As of December 31, 2025 | |||||||
| Accounts payable - related party | $ | $ | ||||||
| Accrued expenses - related party | ||||||||
| Accrued interest - related party | ||||||||
| Total accounts payable and accrued expenses - related party | $ | $ | ||||||
Between
June 6, 2016, and December 1, 2020, the Company received a total of $
On
August 26, 2025, the Company repaid $
On
January 26, 2022, the Company repaid $
On
December 16, 2025, the Company repaid $
Total
loan payable to principal stockholder for as of June 30, 2026, is $
Total
loan payable to this principal stockholder as of December 31, 2025, is $
On
February 2, 2024, the Company repaid $
During
the six months ended June 30, 2026, the Company recorded $
During
the three months ended June 30, 2025, the Company recorded $
As
of June 30, 2026, total interest payable is $
As
of December 31, 2025, total interest payable is $
As
of June 30, 2026, and December 31, 2025, there was $
As
of June 30, 2026, and December 31, 2025, there was $
As
of June 30, 2026, and December 31, 2025, there was $
In
aggregate as of June 30, 2026, and December 31, 2025, the Company owed $
As
of June 30, 2026, and December 31, 2025, the Company owed $
| 27 |
NOTE 9 LOSS FROM UNAUTHORIZED TRANSFER ACTIVITY
During the six months ended June 30, 2026 an unauthorized
third party gained access to the Company’s checking account for Prodigy Silk maintained at a financial institution and fraudulently
initiated transfers totaling $
The Company is pursuing recovery of the fraudulently transferred funds through financial institution and law enforcement. Recovery of the funds is not assured, and accordingly, the Company has not recognized a receivable for any potential recovery as of June 30, 2026. Any recovery will be recognized in the period in which realization is determined to be probable.
Subsequent to June 30, 2026, the Company has recovered
$
Following the incident, the Company closed the compromised account and opened a replacement account at the financial institution and implemented additional safeguards over its treasury function, including eliminating all credit and debit cards linked directly to the Company’s accounts for Prodigy Silk. The incident did not result in unauthorized access to the Company’s information technology systems or to any vendor, or employee data, and the Company does not expect the incident to have a material impact on its financial condition, results of operations, or cash flows.
NOTE 10 SEGMENT INFORMATION
We
operate as
Our Chief Executive Officer, as the CODM, uses consolidated net loss to evaluate our expenditures and monitor budget versus actual results. The monitoring of budget versus actual results and cash on hand are used in assessing the performance of the segment and in establishing resource allocation across the organization.
Factors used in determining the reportable segment include the nature of our operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance.
Significant expenses within net loss include general and administrative, professional fees, officers’ salary, research and development, interest expense, interest income and other, net and income tax expense, which are each separately presented on our consolidated statements of operations.
The following table presents information about the segment’s loss for the three months ended June 30, 2026:
SCHEDULE OF SEGMENT INFORMATION ABOUT SEGMENTS LOSS
| Revenue | $ | - | ||
| Less: | ||||
| Employee expense | ||||
| Occupancy expense | ||||
| Research and development expense | ||||
| Professional services expense | ||||
| Warrants issued for services expense | ||||
| Depreciation and amortization expense | ||||
| Interest Expense | ||||
| Office expense | ||||
| Other segment expense (a) | ||||
| Other income | ( | ) | ||
| Unrealized investment on gold | ||||
| Segment net loss | ||||
| Reconciliation of loss | ||||
| Adjustments and reconciling items | - | |||
| Consolidated net loss | $ |
| (a) |
| 28 |
The following table presents information about the segment’s loss for the three months ended June 30, 2025:
| Revenue | $ | - | ||
| Less: | ||||
| Employee expense | ||||
| Occupancy expense | ||||
| Research and development expense | ||||
| Professional services expense | ||||
| Warrants issued for services expense | ||||
| Depreciation and amortization expense | ||||
| Interest Expense | ||||
| Office expense | ||||
| Other segment expense (a) | ||||
| Interest income | ( | ) | ||
| Unrealized investment on gold | ||||
| Segment net loss | ||||
| Reconciliation of loss | ||||
| Adjustments and reconciling items | - | |||
| Consolidated net loss | $ |
| (a) |
The following table presents information about the segment’s loss for the six months ended June 30, 2026:
| Revenue | $ | - | ||
| Less: | ||||
| Employee expense | ||||
| Occupancy expense | ||||
| Research and development expense | ||||
| Professional services expense | ||||
| Warrants issued for services expense | ||||
| Depreciation and amortization expense | ||||
| Interest Expense | ||||
| Office expense | ||||
| Other segment expense (a) | ||||
| Interest income | ( | ) | ||
| Unrealized investment on gold | ||||
| Segment net loss | ||||
| Reconciliation of loss | ||||
| Adjustments and reconciling items | - | |||
| Consolidated net loss | $ |
| (a) |
Segment Assets:
As
of June 30, 2026, total segment assets amounted to $
The following table presents information about the segment’s loss for the six months ended June 30, 2025:
| Revenue | $ | - | ||
| Less: | ||||
| Employee expense | ||||
| Occupancy expense | ||||
| Research and development expense | ||||
| Professional services expense | ||||
| Warrants issued for services expense | ||||
| Depreciation and amortization expense | ||||
| Interest Expense | ||||
| Office expense | ||||
| Other segment expense (a) | ||||
| Interest income | ( | ) | ||
| Unrealized investment on gold | ( | ) | ||
| Segment net loss | ||||
| Reconciliation of loss | ||||
| Adjustments and reconciling items | - | |||
| Consolidated net loss | $ |
| (a) |
As
of June 30, 2025, total segment assets amounted to $
NOTE 11 SUBSEQUENT EVENTS
The Company has analyzed its operations subsequent to June 30, 2026 through the date these financial statements were issued, and other than those listed below, has determined that it does not have any material subsequent events to disclose.
As
of August 13, 2026, the Company has recovered $
| 29 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
FORWARD-LOOKING INFORMATION
The following information should be read in conjunction with Kraig Biocraft Laboratories, Inc. and its subsidiaries (“we”, “us”, “our”, or the “Company”) condensed unaudited financial statements and the notes thereto contained elsewhere in this report. Information in this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this Form 10-Q that does not consist of historical facts, are “forward-looking statements.” Statements accompanied or qualified by, or containing words such as “may,” “will,” “should,” “believes,” “expects,” “intends,” “plans,” “projects,” “estimates,” “predicts,” “potential,” “outlook,” “forecast,” “anticipates,” “presume,” and “assume” constitute forward-looking statements, and as such, are not a guarantee of future performance.
Forward-looking statements are subject to risks and uncertainties, certain of which are beyond our control. Actual results could differ materially from those anticipated as a result of the factors described in the “Risk Factors” and detailed in our other Securities and Exchange Commission (“SEC”) filings. Risks and uncertainties can include, among others, international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to obtain sufficient financing to continue and expand business operations; the ability to develop technology and products; changes in technology and the development of technology and intellectual property by competitors; the ability to protect technology and develop intellectual property; and other factors referenced in this and previous filings. Consequently, investors should not place undue reliance on forward-looking statements as predictive of future results.
Because of these risks and uncertainties, the forward-looking events and circumstances discussed in this report or incorporated by reference might not transpire. Factors that cause actual results or conditions to differ from those anticipated by these and other forward-looking statements include those more fully described elsewhere in this report and in the “Risk Factors” section of our registration statement on Form S-1.
The Company disclaims any obligation to update the forward-looking statements in this report.
Overview
Kraig Biocraft Laboratories, Inc., a Wyoming corporation, is a corporation organized to develop high strength fibers using recombinant DNA technology for commercial applications including technical textiles. We use genetically engineered silkworms that produce spider silk proteins to create our recombinant spider silk. Applications include performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics and more. We believe that we are a world leader in the research, development, and production of commercially scalable and cost-effective spider silk fiber. Our primary proprietary fiber technology utilizes natural and engineered variants of spider silk produced in domesticated mulberry silkworms. Our business brings twenty-first century biotechnology to the historical silk industry. We are introducing materials with innovative properties into an established commercial ecosystem of silkworm rearing, silk spinning, weaving, and manufacture of garments and other products.
We are using genetic engineering technologies to develop fibers with greater strength, resiliency, and flexibility for use in our target markets, including the specialty fiber and technical textile industries. We believe that the genetically engineered protein-based fibers we seek to produce have properties that are in some ways superior to the materials currently available in the marketplace. Production of our product in commercial quantities holds what we believe to be potential life-saving ballistic resistant material, which we believe is lighter, thinner, more flexible, and tougher than steel. Other potential applications for spider silk based recombinant fibers include use as structural material and for any application in which light weight and high strength are required. We believe that fibers made with recombinant protein-based polymers will make significant inroads into the specialty fiber and technical textile markets.
Through our technologies, the introduction of the gene sequence based on those found in native spider silk, results in a germline transformation and is therefore self-perpetuating. Our recombinant spider silk fibers incorporate the silk proteins found in spider silk with native silkworm silk proteins. This combination of native silkworm proteins combined with spider silk protein structures results in new and unique recombinant silk fibers. This technology is in essence a protein expression platform which has other potential applications including diagnostics and pharmaceutical production. Moreover, our technologies are “green” inasmuch as our fibers and textiles are derived from nature and do not use any petrochemicals as an input into the fibers.
The Report of Independent Registered Public Accounting Firm to our financial statements as of December 31, 2024, and as of December 31, 2025, include an explanatory paragraph stating that our net loss from operations and net capital deficiency at December 31, 2025, raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
| 30 |
Plan of Operations
During the next twelve months, we expect to take the following steps in connection with the further development of our business and the implementation of our plan of operations:
| ● | We plan to accelerate and expand commercial-scale production of our recombinant spider silk. |
| ● | We plan to expand our research and development to accelerate our work in creating next generation materials and to improve the robustness of our recombinant spider silk lines. |
| ● | We plan to create a line of recombinant spider silk fashion wear either under our own brand name or in partnership with existing commercial entities. |
| ● | We plan to continue the expansion of our overseas production operations, including working with local contractors or cooperatives and the hiring of additional direct staff, as needed. |
| ● | We plan to accelerate our microbiology research and development to create more advanced materials. We plan to develop more advanced spider silk and non-spider silk based fibers for select target markets. |
| ● | We will consider buying an established revenue producing company in a compatible business, in order to broaden our financial base and facilitate the commercialization of our products; as of the date hereof, we have not had any formal discussion or entered into any definitive agreements regarding any such purchase. |
| ● | We plan to increase the breadth of our research to include protein expression platform technologies. |
| ● | We plan to actively pursue collaborative research and product testing opportunities with companies in the biotechnology, materials, textile, and other industries. |
| ● | We plan to actively pursue an uplist to a national exchange if such an opportunity presents itself. |
Limited Operating History
We have not previously demonstrated that we will be able to expand our business through an increased investment in our research and development efforts. We cannot guarantee that the research and development efforts described in this filing will be successful. Our business is subject to risks inherent in growing an enterprise, including limited capital resources, risks inherent in the research and development process, risks inherent in working with living organisms, political and legal risks associated with transgenics, and possible rejection of our products in development.
If financing is not available on satisfactory terms, we may be unable to continue our research and development and other operations. Equity financing will result in dilution to existing stockholders.
Standby Equity Purchase Agreement
On January 21, 2025, we entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”). Capitalized terms used herein, but not otherwise defined, have the meaning ascribed to such terms in the SEPA, a copy of which is filed herewith as Exhibit 10.10. As of June 30, 2026, the Company issued a total of 54,166,681 shares of Common Stock in exchange for $5,246,613 under the SEPA.
Pursuant to the SEPA, the Company has the right to sell to the Investor up to $10 million of its shares of common stock, subject to certain limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA. Sales of the shares of common stock to the Investor under the SEPA, and the timing of any such sales, are at the Company’s option, and the Company is under no obligation to sell any shares of common stock to the Investor under the SEPA except in connection with notices that may be submitted by the Investor, in certain circumstances as described below.
| 31 |
Upon the satisfaction of the conditions to the Investor’s purchase obligation set forth in the SEPA, including having a registration statement registering the resale of the shares of common stock issuable under the SEPA declared effective by the SEC, the Company will have the right, but not the obligation, from time to time at its discretion until the SEPA is terminated to direct the Investor to purchase a specified number of shares of common stock (“Advance”) by delivering written notice to the Investor (“Advance Notice”). While there is no mandatory minimum amount for any Advance, it may not exceed an amount equal to 100% of the average of the daily traded amount during the five consecutive trading days immediately preceding an Advance Notice.
In addition to the satisfaction of the conditions, the Investor shall not be obligated to purchase or acquire, and shall not purchase or acquire, any common stock under the SEPA which, when aggregated with all other common stock beneficially owned by the Investor and its affiliates, would result in the beneficial ownership by the Investor and its affiliates (on an aggregated basis) of a number of shares of common stock exceeding 4.99% of the then outstanding voting power or number of common shares. In addition, in no event shall an Advance exceed the number of common shares registered in respect of the transactions contemplated hereby under the registration statement then in effect.
The Company paid the Investor a structuring fee in an amount of $25,000. Additionally, within three days of signing the SEPA (the “Effective Date”), the Company paid a commitment fee in an amount equal to 1.00% of the Commitment Amount (the “Commitment Fee”) consisting of such number of Common Shares that is equal to the Commitment Fee divided by the average of the daily VWAPs of the Common Shares during the 3 Trading Days immediately prior to the Effective Date (the “Commitment Shares”). All of the Commitment Shares have been registered.
The SEPA will automatically terminate on the earliest to occur of (i) 36-month anniversary of the Effective Date or (ii) the date on which the Investor shall have made payment of Advances pursuant to the SEPA for shares of common stock equal to the Commitment Amount. The Company has the right to terminate the SEPA at no cost or penalty upon five (5) trading days’ prior written notice to the Investor, provided that there are no outstanding Advance Notices for which shares of common stock need to be issued. Neither the Company nor the Investor may assign or transfer their respective rights and obligations under the SEPA, and no provision of the SEPA may be modified or waived other than by an instrument in writing signed by both parties.
The SEPA contains customary representations, warranties, conditions, and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.
The net proceeds received by the Company under the SEPA will depend on the frequency and prices at which the Company sells its shares of common stock to the Investor. The Company expects that any proceeds received from such sales to the Investor will be used for working capital and general corporate purposes.
| 32 |
Three months ended June 30, 2026, compared to the three months ended June 30, 2025
|
Three Months Ended June 30, |
% Change Increase | |||||||||||||||
| 2026 | 2025 | Change | (Decrease) | |||||||||||||
| NET REVENUES | $ | - | $ | - | - | - | ||||||||||
| COSTS OF REVENUES | - | - | - | |||||||||||||
| Gross Profit | - | - | - | |||||||||||||
| OPERATING EXPENSES: | ||||||||||||||||
| General and Administrative | 374,381 | 344,035 | 30,346 | 8.82 | % | |||||||||||
| Professional Fees | 69,862 | 43,625 | 26,237 | 60.14 | % | |||||||||||
| Officer’s Salary | 194,821 | 186,197 | 8,624 | 4.63 | % | |||||||||||
| Research and Development | 64,369 | 63,888 | 481 | 0.75 | % | |||||||||||
| Total operating expenses | 703,433 | 637,745 | 65,688 | 10.30 | % | |||||||||||
| Loss from operations | (703,433 | ) | (637,745 | ) | (65,688 | ) | 10.30 | % | ||||||||
| Interest expense | (151,399 | ) | (141,986 | ) | (9,413 | ) | 6.63 | % | ||||||||
| Net change in unrealized appreciation on investment in gold bullion | (74,015 | ) | (10,011 | ) | (64,004 | ) | 639.34 | % | ||||||||
| Gain on sale of gold | - | 62,469 | (62,469 | ) | 100.00 | % | ||||||||||
| Interest income | 19,312 | 1,140 | 18,172 | 1594.04 | % | |||||||||||
| Net Loss | $ | (909,535 | ) | $ | (726,133 | ) | (183,402 | ) | 25.26 | % | ||||||
Our revenue, operating expenses, and net loss from operations for the three month period ended June 30, 2026, as compared to the three month period ended June 30, 2025, were as follows - some balances on the prior period’s combined financial statements have been reclassified to conform to the current period presentation:
Net Revenues: During the three months ended June 30, 2026, we realized $0 of revenues from our business. During the three months ended June 30, 2025, we realized $0 of revenues from our business. The change in revenues between the quarter ended June 30, 2026, and June 30, 2025, was $0 or 0%.
Cost of Revenues: Costs of revenues for the three months ended June 30, 2026, were $0, as compared to $0 for the three months ended June 30, 2025, a change of $0 or 0%.
Gross Profit: During the three months ended June 30, 2026, we realized a gross profit of $0, as compared to $0 for the three months ended June 30, 2025, a change of $0 or 0%.
Research and development expenses: During the three months ended June 30, 2026, we incurred $64,369 of research and development expenses. During the three months ended June 30, 2025, we incurred $63,888 of research and development expenses. This was an increase of $481 or 0.75% in 2026 compared with the same period in 2025. This increase was due to an increase in research spending.
Professional Fees: During the three months ended June 30, 2026, we incurred $69,862 of professional expenses, which increased by $26,237 or 60.14% from $43,625 for the three months ended June 30, 2025. This increase was primarily due to an increase in professional fees and in investor relations services.
Officers Salary: During the three months ended June 30, 2026, officers’ salary expenses increased to $194,821 or 4.63% from $186,197 for the three months ended June 30, 2025. This change was primarily due to 6% annual increase for the Company’s CEO.
General and Administrative Expense: General and administrative expenses increased by $30,346 or 8.82% to $374,381 for the three months ended June 30, 2026, from $344,035 for the three months ended June 30, 2025.
Our general and administrative expenses for the three months ended June 30, 2026, consisted of other general and administrative expenses (which includes expenses such as auto, business development, SEC filings, investor relations, general office, warrants and shares issued for services) of $205,852, travel of $17,804, office salary of $110,725, and consulting of $40,000 for a total of $374,381.
| 33 |
Our general and administrative expenses for the three months ended June 30, 2025, consisted of other general and administrative expenses (which include expenses such as auto, business development, SEC filings, investor relations, general office, warrants and shares issued for services) of $200,262, travel of $15,421, and office salary of $128,352 for a total of $344,035.
Net Change in Unrealized Appreciation and Depreciation on Investment in Gold Bullion: Net change in unrealized appreciation on investment in gold bullion decreased by $64,004 to $74,015 for the three month period ended June 30, 2026, from depreciation of $10,011 for the three month period ended June 30, 2025. The increase was primarily due to a net change in unrealized appreciation on investment in gold bullion.
Interest Expense: Interest expense increased by $9,413 to $151,399 for the three month period ended June 30, 2026, from $141,986 for the three month period ended June 30, 2025. The increase was primarily due to interest on certain Company loans.
Interest Income: Interest income increased by $18,172 to $19,312 for the three month period ended June 30, 2026, from $1,140 for the three month period ended June 30, 2025. The increase was primarily due to an increase in interest on money market fund.
Gain from sale of investment in gold: Gain from sale of investment in gold decreased by $62,469 to $0 for the three months ended June 30, 2026 from $62,469 for the three months ended June 30, 2025. This decrease was due to the Company’s partial sale of its investment in gold.
Net Loss: Net loss increased by $183,402, or 25.26%, to a net loss of $909,535 for the three month period ended June 30, 2026 from a net loss of $726,133 for the three month period ending June 30, 2025. This increase in net loss was primarily attributable to increases in general and administrative expenses, professional fees, officers’ salary, with a slight offset in research and development fees.
Six months ended June 30, 2026, compared to the six months ended June 30, 2025
| Six Months Ended | % Change | |||||||||||||||
| June 30, | Increase | |||||||||||||||
| 2026 | 2025 | Change | (Decrease) | |||||||||||||
| NET REVENUES | $ | - | $ | - | - | - | ||||||||||
| COSTS OF REVENUES | - | - | - | |||||||||||||
| Gross Profit | - | - | - | |||||||||||||
| OPERATING EXPENSES: | ||||||||||||||||
| General and Administrative | 869,947 | 652,886 | 217,061 | 33.25 | % | |||||||||||
| Professional Fees | 140,697 | 106,660 | 34,037 | 31.91 | % | |||||||||||
| Officer’s Salary | 387,219 | 370,927 | 16,292 | 4.39 | % | |||||||||||
| Research and Development | 131,070 | 87,764 | 43,306 | 49.34 | % | |||||||||||
| Total operating expenses | 1,528,933 | 1,218,237 | 310,696 | 25.50 | % | |||||||||||
| Loss from operations | (1,528,933 | ) | (1,218,237 | ) | (310,696 | ) | 25.50 | % | ||||||||
| Interest expense | (299,832 | ) | (282,334 | ) | (17,498 | ) | 6.20 | % | ||||||||
| Net change in unrealized appreciation on investment in gold bullion | (53,607 | ) | 107,477 | (161,084 | ) | -149.88 | % | |||||||||
| Gain on sale of gold | - | 62,469 | (62,469 | ) | 100.00 | % | ||||||||||
| Interest income | 30,117 | 4,459 | 25,658 | 575.42 | % | |||||||||||
| Net Loss | $ | (1,852,255 | ) | $ | (1,326,166 | ) | (526,089 | ) | 39.67 | % | ||||||
Our revenue, operating expenses, and net loss from operations for the three month period ended June 30, 2026, as compared to the six month period ended June 30, 2025, were as follows - some balances on the prior period’s combined financial statements have been reclassified to conform to the current period presentation:
Net Revenues: During the six months ended June 30, 2026, we realized $0 of revenues from our business. During the six months ended June 30, 2025, we realized $0 of revenues from our business. The change in revenues between the quarter ended June 30, 2026, and June 30, 2025, was $0 or 0%.
Cost of Revenues: Costs of revenues for the six months ended June 30, 2026, were $0, as compared to $0 for the six months ended June 30, 2025, a change of $0 or 0%.
Gross Profit: During the six months ended June 30, 2026, we realized a gross profit of $0, as compared to $0 for the six months ended June 30, 2025, a change of $0 or 0%.
Research and development expenses: During the six months ended June 30, 2026, we incurred $131,070 of research and development expenses. During the six months ended June 30, 2025, we incurred $87,764 of research and development expenses. This was an increase of $43,306 or 49.34% in 2026 compared with the same period in 2025. This increase was due to an increase in research spending.
Professional Fees: During the six months ended June 30, 2026, we incurred $140,697 of professional expenses, which increased by $34,037 or 31.91% from $106,660 for the six months ended June 30, 2025. This increase was primarily due to an increase in professional fees and in investor relations services.
Officers Salary: During the six months ended June 30, 2026, officers’ salary expenses increased to $387,219 or 4.39% from $370,927 for the six months ended June 30, 2025. This change was primarily due to 6% annual increase for the Company’s CEO.
General and Administrative Expense: General and administrative expenses increased by $217,061 or 33.25% to $869,947 for the six months ended June 30, 2026, from $652,886 for the six months ended June 30, 2025.
Our general and administrative expenses for the six months ended June 30, 2026, consisted of other general and administrative expenses (which includes expenses such as auto, business development, SEC filings, investor relations, general office, warrants and shares issued for services) of $532,949, travel of $26,274, office salary of $210,724, and consulting of $40,000 for a total of $869,947.
| 34 |
Our general and administrative expenses for the six months ended June 30, 2025, consisted of other general and administrative expenses (which include expenses such as auto, business development, SEC filings, investor relations, general office, warrants and shares issued for services) of $368,423, travel of $26,321, and office salary of $258,142 for a total of $652,886.
Net Change in Unrealized Appreciation and Depreciation on Investment in Gold Bullion: Net change in unrealized appreciation on investment in gold bullion decreased by $161,084 to $53,607 for the six month period ended June 30, 2026, from appreciation of $107,477 for the six month period ended June 30, 2025. The decrease was primarily due to a net change in unrealized appreciation on investment in gold bullion.
Interest Expense: Interest expense increased by $17,498 to $299,832 for the six month period ended June 30, 2026, from $282,334 for the six month period ended June 30, 2025. The increase was primarily due to interest on certain Company loans.
Gain from sale of investment in gold: Gain from sale of investment in gold decreased by $62,469 to $0 for the six months ended June 30, 2026 from $62,469 for the six months ended June 30, 2025. This decrease was due to the Company’s partial sale of its investment in gold.
Interest Income: Interest income increased by $25,658 to $30,117 for the six month period ended June 30, 2026, from $4,459 for the six month period ended June 30, 2025. The increase was primarily due to an increase in interest on money market fund.
Net Loss: Net loss increased by $526,089, or 39.67%, to a net loss of $1,852,255 for the six month period ended June 30, 2026 from a net loss of $1,326,166 for the six month period ending June 30, 2025. This increase in net loss was primarily attributable to increases in general and administrative expenses, professional fees, officers’ salary, and in research and development fees.
Capital Resources and Liquidity
Our financial statements have been presented on the basis that we have a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As presented in the unaudited condensed financial statements, we incurred a net loss of $1,852,255 during the six months ended June 30, 2026, and losses are expected to continue in the near term. The accumulated deficit is $58,561,327 at June 30, 2026. Refer to Note 2 for our discussion of stockholder deficit. We have been funding our operations through private loans and the sale of common stock in private placement transactions. Our cash resources are insufficient to meet our planned business objectives without additional financing. These and other factors raise substantial doubt about our ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of our company to continue as a going concern.
Management anticipates that significant additional expenditures will be necessary to develop and expand our business before significant positive operating cash flows can be achieved. Our ability to continue as a going concern is dependent upon our ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations. At June 30, 2026, we had $3,391,646 of cash on hand. These funds are insufficient to complete our business plan and as a consequence, we will need to seek additional funds, primarily through the issuance of debt or equity securities for cash to operate our business. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in the case of equity financing.
Management has undertaken steps as part of a plan to improve operations with the goal of sustaining our operations for the next twelve months and beyond. These steps include (a) raising additional capital and/or obtaining financing; (b) controlling overhead and expenses; and (c) executing material sales or research contracts. There can be no assurance that the Company can successfully accomplish these steps, and it is uncertain that the Company will achieve a profitable level of operations and obtain additional financing. There can be no assurance that any additional financing will be available to the Company on satisfactory terms and conditions, if at all. As of the date of this Report, we have not entered into any formal agreements regarding the above.
| 35 |
In the event the Company is unable to continue as a going concern, the Company may elect or be required to seek protection from its creditors by filing a voluntary petition in bankruptcy or may be subject to an involuntary petition in bankruptcy. To date, management has not considered this alternative, nor does management view it as a likely occurrence.
Cash and cash equivalents, total current assets, total assets, total current liabilities, and total liabilities as of June 30, 2026, as compared to December 31, 2025, were as follows:
| June 30, 2026 | December 31, 2025 | |||||||
| Cash and Cash Equivalents | $ | 3,391,646 | $ | 1,790,236 | ||||
| Inventory | $ | 134,142 | $ | 29,067 | ||||
| Prepaid expenses | $ | 49,057 | $ | 49,338 | ||||
| Total current assets | $ | 3,574,845 | $ | 1,868,641 | ||||
| Total assets | $ | 4,271,792 | $ | 2,565,540 | ||||
| Total current liabilities | $ | 10,901,744 | $ | 10,445,245 | ||||
| Total liabilities | $ | 11,022,908 | $ | 10,564,498 | ||||
At June 30, 2026, we had a working capital deficit of $7,326,899, compared to a working capital deficit of $8,576,604 at December 31, 2025. Current liabilities increased to $10,901,744 at June 30, 2026, from $10,445,245 at December 31, 2025, primarily as a result of accounts payable - related party.
For the six months ended June 30, 2026, net cash used in operations of $1,128,413 was the result of a net loss of $1,852,255 offset by depreciation expense of $13,324, net change in unrealized depreciation in gold bullions of $53,607, warrants issuance of $270,446, options issued for services of $20,314, imputed interest on related party loans of $36,790, an increase in prepaid expenses of $2,531, an increase in inventory of $105,075, a decrease in operating lease right of use of $33,749, an increase of accrued expenses and other payables-related party of $436,069, increase in accounts payable of $504 and a decrease in operating lease liabilities of $32,347.
For the six months ended June 30, 2025, net cash used in operations of $902,624 was the result of a net loss of $1,326,166 offset by depreciation expense of $11,520, net change in unrealized appreciation in gold bullions of $107,477, gain on sale of gold bullions of $62,469, warrants issuance of $98,069, options issuance of $8,394, imputed interest on related party loans of $40,093, a decrease in prepaid expenses of $13,508, a decrease in operating lease right of use of $27,662, an increase of accrued expenses and other payables-related party of $413,426, increase in accounts payable of $34,514 and a decrease in operating lease liabilities of $28,698.
Net cash used in our investing activities were $42,724 and $143,455 for the six months ended June 30, 2026, and June 30, 2025, respectively. During the six months ended June 30, 2026 the Company had purchase of fixed assets of $42,724. During the six months ended June 30, 2025, the Company had net proceeds from the sale investment in gold of $147,238 and purchase of fixed assets of $3,783.
Our financing activities resulted in a cash inflow of $2,772,547 for the six months ended June 30, 2026, which is represented by $2,772,547 proceeds from the sale of stock.
| 36 |
Our financing activities resulted in a cash inflow of $881,367 for the six months ended June 30, 2025, which is represented by $881,367 proceeds from the sale of stock and $0 payment in debt offering costs.
Critical Accounting Policies
Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the year ended December 31, 2025, for disclosures regarding the Company’s critical accounting policies and estimates, as well as updates further disclosed in our interim financial statements as described in this Form 10-Q.
RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS
ASU 2025-05 — Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets
In July 2025, the FASB issued ASU 2025-05, which provides (1) all entities with a practical expedient and (2) entities other than public business entities with an accounting policy election when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under Topic 606, Revenue from Contracts with Customers.
The practical expedient allows an entity to assume that, when estimating expected credit losses, current conditions as of the balance sheet date remain unchanged for the remaining life of the asset. The accounting policy election permits nonpublic entities that elect the practical expedient to also consider collection activity occurring after the balance sheet date when estimating expected credit losses.
The standard is effective for fiscal years beginning after December 15, 2025, and for interim periods within those annual reporting periods. Early adoption is permitted.
The Company has evaluated ASU 2025-05 and does not expect the standard to have a material impact on its financial condition, results of operations, or cash flows.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures, to require enhanced disclosures that include reportable segment expenses. The amendments in this update provide that a business entity disclose significant segment expenses, segment profit or loss (after significant segment expenses), and allows reporting of additional measures of a segments profit or loss if used in assessing segment performance. Such disclosures apply to entities with a single reportable segment. These amendments were effective for the Company in 2024 and retrospectively to all prior periods using the significant segment expense categories identified. The impact of the adoption of the amendments in this update was not material to the Company’s consolidated financial position and results of operations, as the requirements impact only segment reporting disclosures in the footnotes to the Company’s consolidated financial statements.
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses including purchases of inventory, employee compensation, depreciation and intangible asset amortization in commonly presented expense captions such as cost of sales, selling, general and administrative expense, and research and development. These amendments are effective for the Company for annual periods in 2027, applied prospectively, with early adoption permitted, and interim periods beginning in 2028. The Company intends to adopt the amendments in this update prospectively in 2027 for annual periods and in 2028 for interim periods. The impact of the adoption of the amendments in this update is not expected to be material to the Company’s consolidated financial position and results of operations, as the requirements only require more detailed disclosures in the footnotes to the Company’s consolidated financial statements.
| 37 |
In March 2024, the FASB issued ASU No. 2024-02, Codification Improvements - Amendments to Remove References to the Concepts Statements to remove various references to concepts statements from the FASB Accounting Standards Codification. This guidance is to clarify guidance, simplify wording or structure of guidance, and other minor improvements. These amendments are effective for the Company for annual periods in 2025, applied prospectively, with early adoption and retrospective application permitted. The Company intends to adopt the amendments in this update prospectively in 2025. The impact of the adoption of the amendments in this update is not expected to be material to the Company’s consolidated financial position and results of operations.
In March 2024, the FASB issued ASU No. 2024-01, Compensation - Stock Compensation (Topic 718) - Scope Application of Profits Interest and Similar Awards, to clarify whether profits interest and similar awards should be accounted for in accordance with Topic 718, Compensation - Stock Compensation. The guidance applies to all business entities that issue profits interest awards as compensation to employees or nonemployees in exchange for goods or services. These amendments are effective for the Company for annual and interim periods in 2025, applied prospectively, with early adoption and retrospective application permitted. As the Company does not issue profit interest awards, the impact of the adoption of the amendments in this update is not expected to be material to the Company’s consolidated financial position and results of operations.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures, to require enhanced income tax disclosures to provide information to assess how an entity’s operations and related tax risks, tax planning, and operational opportunities affect its tax rate and prospects for future cash flows. The amendments in this update provide that a business entity disclose (1) a tabular income tax rate reconciliation, using both percentages and amounts, (2) separate disclosure of any individual reconciling items that are equal to or greater than 5% of the amount computed by multiplying the income (loss) from continuing operations before income taxes by the applicable statutory income tax rate, and disaggregation of certain items that are significant and (3) amount of income taxes paid (net of refunds received) disaggregated by federal, state and foreign jurisdictions, including separate disclosure of any individual jurisdictions greater than 5% of total income taxes paid. These amendments are effective for the Company for annual periods in 2025, applied prospectively, with early adoption and retrospective application permitted. The Company intends to adopt the amendments in this update prospectively in 2025. The impact of the adoption of the amendments in this update is not expected to be material to the Company’s consolidated financial position and results of operations, since the amendments require only enhancement of existing income tax disclosures in the footnotes to the Company’s consolidated financial statements.
There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on our consolidated financial position, results of operations or cash flows.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Not applicable.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As of the end of our fiscal quarter ended June 30, 2026, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon those evaluations, management concluded that our disclosure controls and procedures were not effective as of June 30, 2026, to cause the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods prescribed by SEC, and that such information is accumulated and communicated to management, including our chief executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
Going forward from this filing, the Company intends to work on establishing and maintaining disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure.
In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. The design of any system of controls is based, in part, upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
| 38 |
Changes in Internal Control over Financial Reporting
During the quarter covered by this Report, there were no changes in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. However, due to the unauthorized access to our checking account for Prodigy Silk, we have implemented additional safeguards to our accounts (See “Note 9 – Loss from Unauthorized Transfer Activity” for further information). Although we continue to educate our management personnel to increase its ability to comply with the disclosure requirements and financial reporting controls and management oversight of accounting and reporting functions in the future, as we stated in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, we do not expect to remediate the weaknesses in our internal controls over financial reporting until the time when we start to commercialize a recombinant fiber or such time as we have sufficient cash flow to carry out our remediation plans.
Part II - Other Information
Item 1. Legal Proceedings
From time to time, the Company may become a party to litigation or other legal proceedings that it considers to be a part of the ordinary course of its business. To the best of our knowledge, the Company is not currently involved in any legal proceedings that could reasonably be expected to have a material adverse effect on our business, prospects, financial condition, or results of operations; however, the Company may become involved in material legal proceedings in the future.
Item 1A. Risk Factors
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this item. A description of risk factors can be found on our registration statement on Form S-1 located through the SEC EDGAR system or on the company website www.kraiglabs.com/sec-filings/. Information contained on, or that can be accessed through, our website does not constitute a part of this report.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Information regarding any equity securities we have sold during the period covered by this Report that were not registered under the Securities Act of 1933, as amended is set forth below. Each such transaction was exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D promulgated by the SEC, unless otherwise noted. Unless stated otherwise: (i) the securities were offered and sold only to accredited investors; (ii) there was no general solicitation or general advertising related to the offerings; (iii) each of the persons who received these unregistered securities had knowledge and experience in financial and business matters which allowed them to evaluate the merits and risk of the receipt of these securities, and that they were knowledgeable about our operations and financial condition; (iv) no underwriter participated in, nor did we pay any commissions or fees to any underwriter in connection with the transactions; and, (v) each certificate issued for these unregistered securities contained a legend stating that the securities have not been registered under the Securities Act and setting forth the restrictions on the transferability and the sale of the securities.
On April 30, 2026, the Company issued 5,959,847 shares of Common Stock to an employee in exchange for the cashless exercise of 6,000,000 warrants.
On May 4, 2026, the Company signed an agreement with public relations firm Oak Street Communications. Under the terms of that agreement the Company will pay compensation of $22,500 to Oak Street for such services.
Item 3. Defaults upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
(a) Not applicable.
(b) None.
(c)
During the six months ended June 30, 2026, no director or Section 16 officer of the Company
| 39 |
ITEM 6. EXHIBITS
EXHIBIT INDEX
| Exhibit No. | Description | |
| 3.1 | Articles of Incorporation (1) | |
| 3.2 | Articles of Amendment (2) | |
| 3.3 | Articles of Amendment, filed with the Wyoming Secretary of State on November 15, 2013 (3) | |
| 3.4 | Articles of Amendment, filed with the Wyoming Secretary of State on December 17, 2013 (4) | |
| 3.5 | Bylaws (1) | |
| 4.1 | Form of Warrant issued Mr. Jonathan R. Rice (5) | |
| 4.2 | Form of Warrant issued pursuant to that certain Purchase Agreement dated as of March 8, 2019 (7) | |
| 4.3 | Form of Convertible Debenture (8) | |
| 4.4 | Form of Warrant (8) | |
| 4.5 | Form of A&R Convertible Debenture (8) | |
| 10.1 | Employment Agreement between Mr. Jonathan Rice and the Company (6) | |
| 10.2 | Form of Purchase Agreement dated March 8, 2019 (7) | |
| 10.3 | Form of Securities Purchase Agreement (8) | |
| 10.4 | Form of Guaranty Agreement (8) | |
| 10.5 | Form of Security Agreement (8) | |
| 10.6 | Form of IP Security Agreement (8) | |
| 10.7 | Form of Registration Rights Agreement (8) | |
| 10.8 | Strategic Partnership Agreement (portions of the exhibit have been omitted because they (i) are not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed) (9) | |
| 10.9 | Amendment (portions of the exhibit have been omitted because they (i) are not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed) (9) | |
| 10.10 | Standby Equity Purchase Agreement dated as of January 21, 2025, by and between the Company and YA II PN, LTD. (10) | |
| 31.1 | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith) | |
| 31.2 | Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith) | |
| 32.1 | Certification of the Principal Executive Officer pursuant to U.S.C. Section 1350 As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith) | |
| 32.2 | Certification of the Principal Financial Officer pursuant to U.S.C. Section 1350 As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith) | |
| 101.INS | Inline XBRL Instance Document (filed herewith) | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 1. | Incorporated by reference to our Registration Statement on Form SB-2 (Reg. No. 333-146316) filed with the SEC on September 26, 2007. |
| 2. | Incorporated by reference to our Registration Statement on Form S-1 (Reg. No. 333-162316) filed with the SEC on October 2, 2009. |
| 3. | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on November 22, 2013. |
| 4. | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on December 19, 2013. |
| 5. | Incorporated by reference to our Annual Report on Form 10-K filed with the SEC on March 31, 2015. |
| 6. | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on January 21, 2015. |
| 7. | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on March 11, 2019. |
| 8. | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on March 26, 2021. |
| 9. | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on January 26, 2021. |
| 10. | Incorporated by reference to Exhibit 10.1 our Current Report on Form 8-K filed with the SEC on January 21, 2025. |
| 40 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf of the undersigned thereunto duly authorized.
| Kraig Biocraft Laboratories, Inc. | ||
| (Registrant) | ||
| Date: August 13, 2026 | By: | /s/ Kim Thompson |
| Kim Thompson | ||
| President, Chief Executive Officer and | ||
| Chief Financial Officer (Principal Executive Officer and | ||
| Principal Financial and Accounting Officer) | ||
| 41 |